Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 36 (12), 97

Caffeine Enhances the Anti-Tumor Effect of 5-fluorouracil via Increasing the Production of Reactive Oxygen Species in Hepatocellular Carcinoma

Affiliations

Caffeine Enhances the Anti-Tumor Effect of 5-fluorouracil via Increasing the Production of Reactive Oxygen Species in Hepatocellular Carcinoma

Zhilei Wang et al. Med Oncol.

Abstract

The development of drug resistance affecting the prognosis of patients with hepatocellular carcinoma (HCC) leads to low survival rate of HCC patients. Caffeine is reported to have a function of protecting the liver and anti-tumor activity. Therefore, caffeine may be an ideal enhancer for HCC chemotherapy regimens. Our study showed that the combination of caffeine and 5-FU significantly inhibited the proliferation of HCC cells in vivo and in vitro comparing with caffeine or 5-FU monotherapy. The CI values of caffeine (0.5 mM) combined with 5-FU (25, 50 μM) were all less than 1, confirming that the utilization of drug combination has a synergistic inhibitory effect on the proliferation of HCC cells. Meanwhile, results of Western blot and TUNEL assays demonstrated that the apoptotic level of HCC cells in the combined group was significantly increased. The protein expression level of cleaved PARP was up-regulated, while the protein level of Bcl-2 and Bcl-xL was down-regulated. In addition, we found that ROS levels were increased in the 1 mM caffeine and 25 μM 5-FU combination group comparing with the control or single drug group. Taken together, this is the first study to demonstrate that the combination of caffeine and 5-FU inhibits HCC cells proliferation and promotes cellular apoptosis by regulating intracellular ROS production. The present data provides a basis for the application of caffeine combined with 5-FU as a novel chemotherapy regimen for HCC.

Keywords: 5-Fluouracil; Apoptosis; Caffeine; Hepatocellular carcinoma; Proliferation; Reactive oxygen species.

Similar articles

See all similar articles

References

    1. Cancer Sci. 2010 Jun;101(6):1440-6 - PubMed

References

    1. J Exp Clin Cancer Res. 2016 Apr 22;35:71 - PubMed

References

    1. Clin Colorectal Cancer. 2019 Mar;18(1):58-63 - PubMed

References

    1. Aliment Pharmacol Ther. 2019 Mar;49(6):779-788 - PubMed

References

    1. Ann Oncol. 2004 Jul;15(7):1025-32 - PubMed

References

    1. Mol Clin Oncol. 2013 Sep;1(5):853-857 - PubMed

References

    1. Int J Clin Pharmacol Ther. 2013 Jan;51(1):35-7 - PubMed

References

    1. Radiat Oncol. 2017 Mar 7;12(1):47 - PubMed

References

    1. BMB Rep. 2013 Apr;46(4):207-12 - PubMed

References

    1. Front Pharmacol. 2017 Sep 25;8:669 - PubMed

References

    1. World J Gastroenterol. 2015 Apr 7;21(13):3970-7 - PubMed

References

    1. Nutrients. 2019 Mar 24;11(3):null - PubMed

References

    1. Ther Adv Med Oncol. 2017 Oct;9(10):615-626 - PubMed

References

    1. Artif Cells Nanomed Biotechnol. 2018;46(sup1):896-905 - PubMed

References

    1. J Pharmacol Sci. 2016 Aug;131(4):233-40 - PubMed

References

    1. J Nutr Biochem. 2016 Jul;33:63-72 - PubMed

References

    1. Eur J Cancer. 2019 Apr;111:116-125 - PubMed

References

    1. Life Sci. 2018 Jan 15;193:234-241 - PubMed

References

    1. Biol Pharm Bull. 2012;35(3):400-7 - PubMed

References

    1. Int J Sport Nutr Exerc Metab. 2004 Dec;14(6):626-46 - PubMed

References

    1. Xenobiotica. 2015 Jan;45(1):79-87 - PubMed

References

    1. J Am Acad Dermatol. 2019 Aug;81(2):395-402 - PubMed

References

    1. World J Gastroenterol. 2002 Dec;8(6):1029-34 - PubMed

References

    1. Hepatology. 2018 Jan;67(1):422-435 - PubMed

References

    1. Pharmacol Rev. 2006 Sep;58(3):621-81 - PubMed

References

    1. Oxid Med Cell Longev. 2013;2013:791795 - PubMed

References

    1. Anticancer Agents Med Chem. 2015;15(4):484-92 - PubMed

References

    1. Int J Cancer. 2015 Apr 15;136(8):1899-908 - PubMed

References

    1. Eur J Cancer. 2018 Dec;105:71-78 - PubMed

References

    1. Cancer Biol Ther. 2014 May;15(5):524-32 - PubMed

References

    1. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed

References

    1. Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):39-47 - PubMed

References

    1. Neurosci Biobehav Rev. 2016 Dec;71:294-312 - PubMed

MeSH terms

Feedback